BRPI1016257B8 - composições compreendendo finafloxacina para tratamento de infecções óticas - Google Patents

composições compreendendo finafloxacina para tratamento de infecções óticas

Info

Publication number
BRPI1016257B8
BRPI1016257B8 BRPI1016257A BRPI1016257A BRPI1016257B8 BR PI1016257 B8 BRPI1016257 B8 BR PI1016257B8 BR PI1016257 A BRPI1016257 A BR PI1016257A BR PI1016257 A BRPI1016257 A BR PI1016257A BR PI1016257 B8 BRPI1016257 B8 BR PI1016257B8
Authority
BR
Brazil
Prior art keywords
finafloxacin
compositions
infections
treating
optic
Prior art date
Application number
BRPI1016257A
Other languages
English (en)
Inventor
W Stroman David
C Appell Kenneth
A Chowhan Masood
Original Assignee
Alcon Res Ltd
Merlion Pharmaceuticals Gmbh
Merlion Pharmaceuticals Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42752088&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1016257(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd, Merlion Pharmaceuticals Gmbh, Merlion Pharmaceuticals Pte Ltd filed Critical Alcon Res Ltd
Publication of BRPI1016257A2 publication Critical patent/BRPI1016257A2/pt
Publication of BRPI1016257B1 publication Critical patent/BRPI1016257B1/pt
Publication of BRPI1016257B8 publication Critical patent/BRPI1016257B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

composições compreendendo finafloxacino e métodos para tratar infecções oftálmicas, ópticas ou nasais. a presente invenção refere-se a métodos para tratar uma infecção oftálmica, óptica ou nasal compreendendo tratar o tecido infectado com uma composição compreendendo finafloxacino ou um derivado de finafloxacino. a presente invenção da mesma forma refere-se às composições antimicrobianas compreendendo finafloxacino ou um derivado de finafloxacino. as composições são adequadas para o tratamento de infecções oftálmicas, ópticas ou nasais.
BRPI1016257A 2009-07-02 2010-07-02 composições compreendendo finafloxacina para tratamento de infecções óticas BRPI1016257B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22262509P 2009-07-02 2009-07-02
US61/222,625 2009-07-02
PCT/US2010/040956 WO2011003091A1 (en) 2009-07-02 2010-07-02 Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections

Publications (3)

Publication Number Publication Date
BRPI1016257A2 BRPI1016257A2 (pt) 2016-07-12
BRPI1016257B1 BRPI1016257B1 (pt) 2021-03-16
BRPI1016257B8 true BRPI1016257B8 (pt) 2021-05-25

Family

ID=42752088

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1016257A BRPI1016257B8 (pt) 2009-07-02 2010-07-02 composições compreendendo finafloxacina para tratamento de infecções óticas

Country Status (17)

Country Link
US (3) US8536167B2 (pt)
EP (1) EP2448587B1 (pt)
JP (2) JP5784012B2 (pt)
KR (1) KR101541823B1 (pt)
CN (2) CN102470139A (pt)
AR (1) AR077372A1 (pt)
AU (1) AU2010266120B2 (pt)
BR (1) BRPI1016257B8 (pt)
CA (1) CA2765852C (pt)
CL (1) CL2011003327A1 (pt)
ES (1) ES2694775T3 (pt)
MX (1) MX2012000136A (pt)
RU (1) RU2570731C2 (pt)
TW (1) TWI460181B (pt)
UY (1) UY32758A (pt)
WO (1) WO2011003091A1 (pt)
ZA (1) ZA201109492B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32758A (es) * 2009-07-02 2010-10-29 Alcon Res Ltd Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
US20150174137A1 (en) * 2010-06-02 2015-06-25 Alcon Research, Ltd. Compositions for treating microbial infections
US8765725B2 (en) 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CN104350063B (zh) 2012-05-08 2018-01-05 尼科斯眼药公司 疏水性治疗剂的制剂、其制备方法及应用
US9504691B2 (en) * 2012-12-06 2016-11-29 Alcon Research, Ltd. Finafloxacin suspension compositions
US9815865B2 (en) 2013-01-07 2017-11-14 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
US20150045739A1 (en) * 2013-08-12 2015-02-12 Novartis Ag Method for treating otic infections after tympanostomy tube placement
DE102014115951A1 (de) * 2014-11-03 2016-05-04 Merlion Pharmaceuticals Pte Ltd. Zusammensetzungen, die Finafloxacin und Tris enthalten
DE102015100068A1 (de) 2015-01-06 2016-07-07 Merlion Pharmaceuticals Pte Ltd. Finafloxacin zur verwendung bei der behandlung von harnwegsinfektionen
WO2017189967A1 (en) * 2016-04-29 2017-11-02 University Of Houston System Compositions, methods and kits for treating a contact lens
WO2018078408A1 (en) 2016-10-28 2018-05-03 The Nielsen Company (Us), Llc Reducing scale estimate errors in shelf images

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2832535B2 (ja) * 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
US5421818A (en) * 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
US6156728A (en) * 1996-11-01 2000-12-05 Genentech, Inc. Treatment of inner ear hair cells
DE19652239A1 (de) * 1996-12-16 1998-06-18 Bayer Ag Verwendung von 7-(2-Oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-chinolon- und -naphthyridoncarbonsäure-Derivaten zur Therapie von Helicobacter-pylori-Infektionen und den damit assoziierten gastroduodenalen Erkrankungen
AR020661A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Una composicion farmaceutica topica oftalmica, otica o nasal y el uso de la misma para la manufactura de un medicamento
US6440964B1 (en) * 1998-09-30 2002-08-27 Alcon Manufacturing, Ltd. Compositions and methods for treating ophthalmic and otic infections
US6509327B1 (en) * 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
JP2006289070A (ja) * 2005-03-18 2006-10-26 Santen Pharmaceut Co Ltd キノロン系抗菌化合物含有製品
PT1901749T (pt) * 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Fluoroquinolonas aerossolizadas e suas utilizações
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
UY32758A (es) * 2009-07-02 2010-10-29 Alcon Res Ltd Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas

Also Published As

Publication number Publication date
UY32758A (es) 2010-10-29
AU2010266120A1 (en) 2012-02-02
KR20120114211A (ko) 2012-10-16
RU2012103458A (ru) 2013-08-10
KR101541823B1 (ko) 2015-08-04
AU2010266120B2 (en) 2014-02-06
EP2448587B1 (en) 2018-08-22
US20110003803A1 (en) 2011-01-06
WO2011003091A1 (en) 2011-01-06
US20150328229A1 (en) 2015-11-19
JP2015134827A (ja) 2015-07-27
US9993483B2 (en) 2018-06-12
US8536167B2 (en) 2013-09-17
CA2765852A1 (en) 2011-01-06
MX2012000136A (es) 2012-02-08
JP5784012B2 (ja) 2015-09-24
CN105687111A (zh) 2016-06-22
RU2570731C2 (ru) 2015-12-10
JP2012532115A (ja) 2012-12-13
CA2765852C (en) 2014-08-26
CL2011003327A1 (es) 2013-01-25
ZA201109492B (en) 2013-03-27
US20130331385A1 (en) 2013-12-12
CN102470139A (zh) 2012-05-23
EP2448587A1 (en) 2012-05-09
US9119859B2 (en) 2015-09-01
BRPI1016257B1 (pt) 2021-03-16
AR077372A1 (es) 2011-08-24
BRPI1016257A2 (pt) 2016-07-12
TW201102395A (en) 2011-01-16
ES2694775T3 (es) 2018-12-27
TWI460181B (zh) 2014-11-11

Similar Documents

Publication Publication Date Title
BRPI1016257B8 (pt) composições compreendendo finafloxacina para tratamento de infecções óticas
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
EA201390198A1 (ru) Гетероциклическое соединение
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
BRPI1009637A2 (pt) composto, composição e uso de um composto
DOP2011000102A (es) Compuestos heteroaromaticos espirociclicos fusionados para el tratamiento de infecciones bacterianas
EA201491548A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112012013854A2 (pt) derivados de oxazina.
EA201170349A1 (ru) Модуляторы mif
BR112014005700A2 (pt) composições oftálmicas compreendendo derivados de prostaglandina f2 alfa e ácido hialurônico
EA201170689A1 (ru) Противомикробные композиции
MX2013001204A (es) Compuesto para el tratamiento/prevencion de enfermedades inflamatorias oculares.
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
DK2257275T3 (da) Ketorolactromethaminsammensætninger til behandling eller forebyggelse af øjensmerte
UY32457A (es) Vacuna del virus del dengue inactivado
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
NZ607580A (en) N-heteroaryl compounds
BR112013010136A2 (pt) vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma
BR112019024549A2 (pt) compostos derivados de glicopeptídeo e usos dos mesmos
BR112013024974A2 (pt) composto, composição farmacêutica, método para o tratamento de infecções virais, e, processo para preparar um composto
UA107346C2 (en) Use of nifuratel to treat infections caused by atopobium species
UA113151C2 (xx) Застосування композиції, що містить антимікробний поліпептид, у виробництві лікарського засобу
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25A Requested transfer of rights approved

Owner name: MERLION PHARMACEUTICALS PTE LTD. (SG)

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: MERLION PHARMACEUTICALS GMBH (DE)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/07/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF